Stewart Abbot, CSO, Turnstone Biologics
Laurie Adami, CAR-T Patient, Independent
Sean Armour, Head of Discovery, Spark Therapeutics
Monica Avila, Sr. Director, CMC Alliance and Project Management, Cellenkos
Daniel Baker, PhD Candidate, June Lab, University of Pennsylvania School Of Medicine
Ricardo Baptista, Chief Technology Officer, Independent
Francesca Barone, CSO, Candel Therapeutics
Clayton Beard, Chief Scientific Officer and Site Head, BridgeBio Gene Therapy
Allyson Berent, Chief Science Officer, Foundation for Angelman Syndrome Therapeutics, Foundation for Angelman Syndrome Therapeutics
Jaap Boelens, Chief, Stem Cell Transplantation And Cellular Therapies Pediatrics, Memorial Sloan-Kettering Cancer Center
Martin Bonamino, Head of the Cell and Gene Therapy Program at the National Cancer Institute of Brazil, National Cancer Institute of Brazil
Tara Britt, President & Founder, Rare Disease Innovations Institute, Inc.
P.J. BROOKS, Deputy Director of the NCATS Division of Rare Diseases Research Innovation, National Institutes of Health
Omer Butt, Vice President, Regulatory Affairs, CytoImmune Therapeutics
Lizette Caballero, Associate Director, Clinical Cell Therapy Liaison (CTL), Johnson & Johnson Pharmaceutical R&D
Daniel Chung, Chief Medical Officer�, SparingVision
Karishma Contractor, Senior Manager - Audit and Inspection Management, Vertex Pharmaceuticals
Cheryl Cox, Cell Therapy Core Operations Director, Moffitt Cancer Center
Bryon Daily, Senior Manager, Patient & Professional Programs, The Leukemia & Lymphoma Society
Eric Michael David, Chief Executive Officer, BridgeBio Gene Therapy
Michele de Guise, President and Chief Executive Officer, INESSS
Colleen Delaney, Founder, Chief Scientific Officer, Deverra Therapeutics, Inc.
Boro Dropulic, Executive Director and Co-founder, Caring Cross
Jerry Eriksson, Associate Director, AstraZeneca
Allen Feng, Chief Scientific Officer, HebeCell Corporation
Marcie Finney, Executive Director, Cleveland Cord Blood Center
Gregory Fiore, Former CEO, Exacis Biotherapeutics
Miguel Forte, CEO, Kiji Tx
Sarah Glass, Chief Operating Officer, n-Lorem Foundation
David Greenwald, Vice President Of Business Development, Deerfield Management
Lore Gruenbaum, Vice President of Research Therapy Acceleration Program, The Leukemia and Lymphoma Society
Nader Halim, CEO, Innervace
Patrick Hanley, Chief and Director, Cellular Therapy Program, Children's National Medical Center
Karin Hoelzer, Director of Policy and Regulatory Affairs, National Organization for Rare Disorders
Robert Hofmeister, Chief Scientific Officer, Myeloid Therapeutics
Kathy Ivey, Vice President of Gene Therapy Research, Tenaya Therapeutics
Jie Jia, Vice President, Strategic Alliances and Operations, Carsgen Therapeutics
Scott Jones, VP of Scientific Affairs, BioBridge Global
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
Angela Justice, Chief People Officer, Justice Group Advisors
Stephan Kadauke, Assistant Professor of Clinical Pathology and Lab Medicine, The Children's Hospital of Philadelphia
Annahita Keravala, Founder, Chief Scientific Officer, Genascence
Sven Kili, Chief Development Officer, CCRM & Principal, CCRM
Roland Kolbeck, Chief Scientific Officer, Spirovant Sciences
Antti Kourula, Global Vice President, Commercial Development, Hematology, CSL Behring
Stephan Krause, Bristol Myers Squibb
Ashley Krull, Associate Director, Cell Therapy Manufacturing and Engineering, The Ohio State University Wexner Medical Center
Joanne Kurtzberg, Professor Of Pediatrics And Pathology; Director, Marcus Center For Cellular Cures,, Duke University Medical Center
Lawrence Lamb, Executive Vice President And Chief Scientific Officer, in8bio
Jane Lebkowski, President, Regenerative Patch Technologies
Bruce Levine, Professor, Perelman School of Medicine University of Pennsylvania
Hy Levitsky, President of Research & Development, Century Therapeutics
Bethany Lilly, Executive Director Public Policy, Govt Affairs & Regulatory, Leukemia & Lymphoma Society
Jason Lott, VP, Global Integrated Evidence Generation, Specialty Medicine, Integrated Care, and Cell-Gene Therapy, Bayer
Steven Lucio, Senior Principal, Vizient
Raymond Luke, Director, MSAT, Verismo Therapeutics
Leslie Meltzer, Chief Medical Officer, Orchard Therapeutics
David Morrow, manager, EATRIS
Snehal Naik, Head of Regulatory Policy; Strategy Leader (Ocular), Spark Therapeutics
Susan B Nichols, Chairman of the Board, Rare Disease Innovations Institute, Inc.
Charis Ober, Founder And Executive Director, Save the Cord Foundation
Raphael Ognar, President & Chief Executive Officer, Co-Founder, NKILT Therapeutics Inc.
Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)
Paul Orchard, Professor of Pediatrics, University of Minnesota
Parimal Pande, Associate Scientific Director, Johnson & Johnson
Kinnari Patel, President & COO, Rocket Pharma
Kruti Patel, Associate Director, Immunology, Solid Biosciences
Nicole Paulk, Chief Executive Officer, Siren Biotechnology
David Peritt, Chief Scientific Officer, Lupagen
Christina Pham, Director, Preclinical Science, Atara Biotherapeutics
Amanda Placone, Senior Director External Innovation, Eli Lilly and Company
David Porter, Director, Cell Therapy and Transplant, University of Pennsylvania
Frederick Porter, Chief Technical Officer, Taysha Gene Therapies
Brian Price, Chief Technology Officer, Armatus Bio, Inc
Jack Ragheb, Senior Vice President Translational Sciences and Medicine, NexImmune Inc
Satinder Rawat, Excision Biotherapeutics
Albert Ribickas, Assistant Operations manager Cell Therapies, Moffitt Cancer Center
Robert Richards, Corporate Director of The Center for Cell Therapy and Transplant, University Of Pennsylvania Health System
Kate Rochlin, Chief Operating Officer, in8bio
Holger Russ, Associate Professor, University of Florida
Tara Sadeghi, Chief Operating Officer, Cellenkos
Sumona (Fed) Sarkar, Biomedical Engineer, NIST USA
Machi Scaradavou, Medical Director Of The National Cord Blood Program, New York Blood Center
Sonja Schrepfer, Scientific Founder and Senior Vice President at Sana Biotechnology (Head of Hypo-Immune Platform), Sana Biotechnology
Yossi Schwartz, Director, Transfusion Services, Moffitt Cancer Center
Don Seigel, Professor, Pathology & Laboratory Medicine, University of Pennsylvania School Of Medicine
Robert Sexton, Vice President, Program and Alliance Leadership, Mustang Bio
Ruchi Sharma, National Eye Institute NEI
Adam Shaywitz, Chief Medical Officer, BridgeBio Gene Therapy
Devyn Smith, Chief Executive Officer, Arbor Biotechnologies
Andrea Sobjak, Director of Viral Vector Analytics, Johnson & Johnson Pharmaceutical R&D
Morten Sogaard, President, Research and Technical Operations, Astellas Gene Therapies
Joseph Stavas, Senior Vice President of Clinical Development, ProKidney
Michele Stone, Senior Vice President of Research and Development, Kriya Therapeutics
Leah Szumita, Director, Clinical Trial Support Center, The Leukemia & Lymphoma Society
Paul Peter Tak, President & Chief Executive Officer, Candel Therapeutics
Sarah Thomas, Sr Vice President of Quality�, REGENXBIO
Arun Upadhyay, Chief Scientific Officer, Ocugen
Mark Veich, VP, Philanthropy & Executive Director, The Deerfield Foundation and President of Advancium Health, Deerfield Foundation, Advancium Health
Nelly Viseux, VP, Cell Therapies Development, Manufacturing, Supply & Quality, 2seventy bio
Jim Wang, VP, Global Regulatory Strategy, Regeneron
Jane Wang, Head of Delivery Sciences, Tessera Therapeutics
Brent Warner, President of Gene Therapy, Poseida Therapeutics, Inc.
Thomas Weber, Senior Director of Viral Platforms, Spark Therapeutics
Daniel Weiss, Professor of Medicine, Pulmonary Medicine Department of Medicine, University of Vermont
Tom Wilton, Chief Business Officer, Carisma Therapeutics
Tim Wiltshire, Section Director, IMPACT Lab, Mayo Clinic
Nan Zhang, Chief, Cell Therapy Manufacturing Section, Center for Cellular Engineering, National Institute of Health
Jie Zhang, Head of Global Value and Access, Cell & Gene, Oncology, Novartis
Get Involved with the Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events